1
|
Abstract
Cystic fibrosis (CF) is a rare autosomal-recessive disorder manifested as multisystem organ dysfunction. The cystic fibrosis transmembrane conductance regulator (CFTR) protein functions as an ion transporter on the epithelium of exocrine glands, regulating secretion viscosity. The CFTR gene, encoded on chromosome 7, is required for the production and trafficking of the intact and functional CFTR protein. Literally thousands of human CFTR allelic mutations have been identified, each with varying impact on protein quality and quantity. As a result, individuals harboring CFTR mutations present with a spectrum of symptoms ranging from CF to normal phenotypes. Those with loss of function but without full CF may present with CFTR-related disorders (CFTR-RDs) including male infertility, sinusitis, pancreatitis, atypical asthma and bronchitis. Studies have demonstrated associations between higher rates of CFTR mutations and oligospermia, epididymal obstruction, congenital bilateral absence of the vas deferens (CBAVD), and idiopathic ejaculatory duct obstruction (EDO). Genetic variants are detected in over three-quarters of men with CBAVD, the reproductive abnormality most classically associated with CFTR aberrations. Likewise, nearly all men with clinical CF will have CBAVD. Current guidelines from multiple groups recommend CFTR screening in all men with clinical CF or CBAVD though a consensus on the minimum number of variants for which to test is lacking. CFTR testing is not recommended as routine screening for men with other categories of infertility. While available CFTR panels include 30 to 96 of the most common variants, complete gene sequencing should be considered if there is a high index of suspicion in a high-risk couple (e.g., partner is CFTR mutation carrier). CF treatments to date have largely targeted end-organ complications. Novel CFTR-modulator treatments aim to directly target CFTR protein dysfunction, effectively circumventing downstream complications, and possibly preventing symptoms like vasal atresia at a young age. Future gene therapies may also hold promise in preventing or reversing genetic changes that lead to CF and CFTR-RD.
Collapse
Affiliation(s)
- Jared M Bieniek
- Tallwood Urology & Kidney Institute, Hartford HealthCare, Hartford, CT, USA
| | - Craig D Lapin
- Division of Pediatric Pulmonology, Connecticut Children's Medical Center, Hartford, CT, USA.,Department of Pediatrics, University of Connecticut, Farmington, CT, USA
| | - Keith A Jarvi
- Division of Urology, Department of Surgery, Mount Sinai Hospital and Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
2
|
Abstract
The availability of the human genome sequence and tools for interrogating individual genomes provide an unprecedented opportunity to apply genetics to medicine. Mendelian conditions, which are caused by dysfunction of a single gene, offer powerful examples that illustrate how genetics can provide insights into disease. Cystic fibrosis, one of the more common lethal autosomal recessive Mendelian disorders, is presented here as an example. Recent progress in elucidating disease mechanism and causes of phenotypic variation, as well as in the development of treatments, demonstrates that genetics continues to play an important part in cystic fibrosis research 25 years after the discovery of the disease-causing gene.
Collapse
|
3
|
Ramasamy R, Lipshultz LI. Cystic fibrosis transmembrane regulator mutation and congenital bilateral absence of the vas deferens: a bad combination for successful intracytoplasmic sperm injection outcomes. Fertil Steril 2014; 101:1246. [PMID: 24636394 DOI: 10.1016/j.fertnstert.2014.02.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Accepted: 02/07/2014] [Indexed: 11/24/2022]
|
4
|
Fernandes CJCDS, Jardim CVP, Hovnanian A, Hoette S, Morinaga LK, Souza R. Schistosomiasis and pulmonary hypertension. Expert Rev Respir Med 2014; 5:675-81. [DOI: 10.1586/ers.11.58] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
5
|
Ooi CY, Dupuis A, Ellis L, Jarvi K, Martin S, Ray PN, Steele L, Kortan P, Gonska T, Dorfman R, Solomon M, Zielenski J, Corey M, Tullis E, Durie P. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis? Thorax 2013; 69:254-60. [PMID: 24149827 DOI: 10.1136/thoraxjnl-2013-203832] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND The phenotypic spectrum of cystic fibrosis (CF) has expanded to include patients affected by single-organ diseases. Extensive genotyping and nasal potential difference (NPD) testing have been proposed to assist in the diagnosis of CF when sweat testing is inconclusive. However, the diagnostic yield of extensive genotyping and NPD and the concordance between NPD and the sweat test have not been carefully evaluated. METHODS We evaluated the diagnostic outcomes of genotyping (with 122 mutations included as disease causing), sweat testing and NPD in a prospectively ascertained cohort of undiagnosed patients who presented with chronic sino-pulmonary disease (RESP), chronic/recurrent pancreatitis (PANC) or obstructive azoospermia (AZOOSP). RESULTS 202 patients (68 RESP, 42 PANC and 92 AZOOSP) were evaluated; 17.3%, 22.8% and 59.9% had abnormal, borderline and normal sweat chloride results, respectively. Only 17 (8.4%) patients were diagnosable as having CF by genotyping. Compared to sweat testing, NPD identified more patients as having CF (33.2%) with fewer borderline results (18.8%). The level of agreement according to kappa statistics (and the observed percentage of agreement) between sweat chloride and NPD in RESP, PANC and AZOOSP subjects was 'moderate' (65% observed agreement), 'poor' (33% observed agreement) and 'fair' (28% observed agreement), respectively. The degree of agreement only improved marginally when subjects with borderline sweat chloride results were excluded from the analysis. CONCLUSIONS The diagnosis of CF or its exclusion is not always straightforward and may remain elusive even with comprehensive evaluation, particularly among individuals who present at an older age with single-organ manifestations suggestive of CF.
Collapse
Affiliation(s)
- Chee Y Ooi
- Physiology and Experimental Medicine, Research Institute, The Hospital for Sick Children, , Toronto, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
Several diseases have been clinically or genetically related to cystic fibrosis (CF), but a consensus definition is lacking. Here, we present a proposal for consensus guidelines on cystic fibrosis transmembrane conductance regulator (CFTR)-related disorders (CFTR-RDs), reached after expert discussion and two dedicated workshops. A CFTR-RD may be defined as "a clinical entity associated with CFTR dysfunction that does not fulfil diagnostic criteria for CF". The utility of sweat testing, mutation analysis, nasal potential difference, and/or intestinal current measurement for the differential diagnosis of CF and CFTR-RD is discussed. Algorithms which use genetic and functional diagnostic tests to distinguish CF and CFTR-RDs are presented. According to present knowledge, congenital bilateral absence of vas deferens (CBAVD), acute recurrent or chronic pancreatitis and disseminated bronchiectasis, all with CFTR dysfunction, are CFTR-RDs.
Collapse
|
7
|
Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2010; 182:614-26. [PMID: 20448091 PMCID: PMC2937235 DOI: 10.1164/rccm.201001-0092oc] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2010] [Accepted: 05/06/2010] [Indexed: 02/04/2023] Open
Abstract
RATIONALE Long-term survivors of cystic fibrosis (CF) (age > 40 yr) are a growing population comprising both patients diagnosed with classic manifestations in childhood, and nonclassic phenotypes typically diagnosed as adults. Little is known concerning disease progression and outcomes in these cohorts. OBJECTIVES Examine effects of age at diagnosis and gender on disease progression, setting of care, response to treatment, and mortality in long-term survivors of CF. METHODS Retrospective analysis of the Colorado CF Database (1992-2008), CF Foundation Registry (1992-2007), and Multiple Cause of Death Index (1992-2005). MEASUREMENTS AND MAIN RESULTS Patients with CF diagnosed in childhood and who survive to age 40 years have more severe CFTR genotypes and phenotypes compared with adult-diagnosed patients. However, past the age of 40 years the rate of FEV(1) decline and death from respiratory complications were not different between these cohorts. Compared with males, childhood-diagnosed females were less likely to reach age 40 years, experienced faster FEV(1) declines, and no survival advantage. Females comprised the majority of adult-diagnosed patients, and demonstrated equal FEV(1) decline and longer survival than males, despite a later age at diagnosis. Most adult-diagnosed patients were not followed at CF centers, and with increasing age a smaller percentage of CF deaths appeared in the Cystic Fibrosis Foundation Registry. However, newly diagnosed adults demonstrated sustained FEV(1) improvement in response to CF center care. CONCLUSIONS For patients with CF older than 40 years, the adult diagnosis correlates with delayed but equally severe pulmonary disease. A gender-associated disadvantage remains for females diagnosed in childhood, but is not present for adult-diagnosed females.
Collapse
Affiliation(s)
- Jerry A Nick
- Adult Cystic Fibrosis Program, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Lapa M, Dias B, Jardim C, Fernandes CJ, Dourado PM, Figueiredo M, Farias A, Tsutsui J, Terra-Filho M, Humbert M, Souza R. Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. Circulation 2009; 119:1518-23. [PMID: 19273723 DOI: 10.1161/circulationaha.108.803221] [Citation(s) in RCA: 116] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background —
Schistosomiasis is a highly prevalent disease with >200 million infected people. Pulmonary hypertension is one of the pulmonary manifestations in this disease, particularly in its hepatosplenic presentation. The aim of this study was to determine the prevalence of pulmonary hypertension in schistosomiasis patients with the hepatosplenic form of the disease.
Methods and Results —
All patients with hepatosplenic schistosomiasis followed up at the gastroenterology department of our university hospital underwent echocardiographic evaluation to search for pulmonary hypertension. Patients presenting with systolic pulmonary artery pressure >40 mm Hg were further evaluated through right heart catheterization. Our study showed an 18.5% prevalence of patients with elevated systolic pulmonary artery pressure at echocardiography. Invasive hemodynamics confirmed the presence of pulmonary hypertension in 7.7% (95% confidence interval, 3.3 to 16.7) of patients, with a prevalence of precapillary (arterial) pulmonary hypertension of 4.6% (95% confidence interval, 1.5 to 12.7).
Conclusions —
Our study reinforces the role of echocardiography as a screening tool in the investigation of pulmonary hypertension, together with the need for invasive monitoring for a proper diagnosis. We conclude that hepatosplenic schistosomiasis may account for one of the most prevalent forms of pulmonary hypertension worldwide, justifying the development of further studies to evaluate the effect of specific pulmonary hypertension treatment in this particular form of the disease.
Collapse
Affiliation(s)
- Monica Lapa
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Bruno Dias
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Carlos Jardim
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Caio J.C. Fernandes
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Paulo M.M. Dourado
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Magda Figueiredo
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Alberto Farias
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Jeane Tsutsui
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Mario Terra-Filho
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Marc Humbert
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| | - Rogerio Souza
- From the Pulmonary Department (M.L., B.D., C.J., C.J.C.F., M.T.-F., R.S.) and Cardiology Department (P.M.M.D., M.F., J.T.), Heart Institute, and Gastroenterology Department (A.F.), University of Sao Paulo Medical School, Sao Paulo, Brazil; and Université Paris-Sud 11 (M.H., R.S.), Pulmonary Department, Hôpital Antoine-Beclere, Clamart, France
| |
Collapse
|
9
|
Abstract
The treatment of cystic fibrosis has improved significantly over the past three decades. Median survival has improved by decades and is now estimated to be 37 years. Many factors contribute to improvements in disease severity and outcome. This paper reviews the current evidence of three groups of important factors: genetic, environmental and healthcare related.
Collapse
Affiliation(s)
- Linda L Wolfenden
- Emory Cystic Fibrosis Center, Emory University, Atlanta, Georgia, USA.
| | | |
Collapse
|
10
|
Abstract
Cystic fibrosis transmembrane conductance regulator-related disorders encompass a disease spectrum from focal male reproductive tract involvement in congenital absence of the vas deferens to multiorgan involvement in classic cystic fibrosis. The reproductive, gastrointestinal, and exocrine manifestations of cystic fibrosis transmembrane conductance regulator deficiency are correlated with CFTR genotype, whereas the respiratory manifestations that are the main cause of morbidity and mortality in cystic fibrosis are less predictable. Molecular genetic testing of CFTR has led to new diagnostic strategies and will enable targeting of molecular therapies now in development. Older diagnostic methods that measure sweat chloride and nasal potential difference nonetheless remain important because of their sensitivity and specificity. In addition, the measurement of immunoreactive trypsinogen and the genotyping of CFTR alleles are key to newborn screening programs because of low cost. The multiorgan nature of cystic fibrosis leads to a heavy burden of care, thus therapeutic regimens are tailored to the specific manifestations present in each patient. The variability of cystic fibrosis lung disease and the variable expressivity of mild CFTR alleles complicate genetic counseling for this autosomal recessive disorder. Widespread implementation of newborn screening programs among populations with significant cystic fibrosis mutation carrier frequencies is expected to result in increasing demands on genetic counseling resources.
Collapse
|
11
|
O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R. Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics 2006; 118:1260-5. [PMID: 16951024 DOI: 10.1542/peds.2006-0399] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
We report 3 cystic fibrosis newborn screen-positive infants with the DeltaF508/R117H-7T genotype who had Pseudomonas aeruginosa detected in oropharyngeal cultures early in life and a fourth who had pulmonary symptoms and Gram-negative growth on multiple oropharyngeal cultures. All 4 patients were followed prospectively from the time of genetic diagnosis. As many regions implement newborn screening for cystic fibrosis, there is concern regarding which mutations should be included in genetic panels used to make the cystic fibrosis diagnosis. Some have recommended that mutations not specifically associated with classic cystic fibrosis be excluded. Our cases highlight the importance of considering keeping so-called mild mutations on cystic fibrosis newborn screening panels and the need to follow children with these mutations closely.
Collapse
Affiliation(s)
- Brian P O'Sullivan
- Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
| | | | | | | | | |
Collapse
|
12
|
Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006; 174:787-94. [PMID: 16840743 PMCID: PMC2648063 DOI: 10.1164/rccm.200509-1377oc] [Citation(s) in RCA: 124] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
AIM To examine the relationship between cystic fibrosis transmembrane regulator gene mutations (CFTR) and in vivo transepithelial potentials. METHODS We prospectively evaluated 162 men including 31 healthy subjects, 21 obligate heterozygotes, 60 with congenital bilateral absence of the vas deferens (CBAVD) and 50 with CF by extensive CFTR genotyping, sweat chloride and nasal potential difference testing. RESULTS Six (10%) men with CBAVD carried no CFTR mutations, 18 (30%) carried one mutation, including the 5T variant, and 36 (60%) carried mutations on both alleles, for a significantly higher rate carrying one or more mutations than healthy controls (90% versus 19%, p < 0.001). There was an overlapping spectrum of ion channel measurements among the men with CBAVD, ranging from values in the control and obligate heterozygote range at one extreme, to values in the CF range at the other. All pancreatic-sufficient patients with CF and 34 of 36 patients with CBAVD with mutations on both alleles carried at least one mild mutation. However, the distribution of mild mutations in the two groups differed greatly. Genotyping, sweat chloride and nasal potential difference (alone or in combination) excluded CF in all CBAVD men with no mutations. CF was confirmed in 56% and 67% of CBAVD men carrying 1 and 2 CFTR mutations, respectively. CONCLUSION Abnormalities of CFTR transepithelial function correlate with the number and severity of CFTR gene mutations.
Collapse
|
13
|
Armstrong DS, Hook SM, Jamsen KM, Nixon GM, Carzino R, Carlin JB, Robertson CF, Grimwood K. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005; 40:500-10. [PMID: 16208679 DOI: 10.1002/ppul.20294] [Citation(s) in RCA: 159] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Controversy exists over whether the lower airway inflammation that characterizes cystic fibrosis (CF) is initiated primarily by the genetic defect. To determine if inflammation precedes infection, we examined bronchoalveolar lavage (BAL) fluid cytology, cytokines (interleukin (IL)-1beta, IL-4, IL-5, IL-6, IL-8, IL-10, and tumor necrosis factor-alpha), and free neutrophil elastase activity from 70 CF (aged 1.5-71 months) children detected by newborn screening and 19 (aged 2.0-48 months) controls with chronic stridor. CF subjects were selected and categorized as pristine (13 aged </= 6 months, lacking prior respiratory symptoms and exposure to antibiotics, and without respiratory pathogens on BAL), infected (42 with viruses or >/= 10(5) colony-forming units/ml of pathogenic bacteria in BAL), and uninfected (15 aged > 6 months, asymptomatic, not taking antibiotics at bronchoscopy, and free of pathogens in their BAL). To further resolve if inflammation develops without infection, inflammatory mediators in paired annual BAL samples from 38 CF subjects were measured, and results were grouped according to whether BAL showed persistence (n = 6), acquisition (n = 8), clearance (n = 13), or absence (n = 11) of infection. While pristine, uninfected, and control subjects had similar BAL profiles, infected patients showed elevated inflammatory indices, including increased IL-10 (P < 0.001). Pristine subjects had the fewest signs of inflammation. Analysis of BAL pairs found differences between the four infection groups for changes in neutrophil percentages, IL-8 (P < 0.001), and free neutrophil elastase (P = 0.009). Infection was associated with elevated inflammatory mediators in BAL fluid. In contrast, minimal or reduced signs of inflammation accompanied absence of eradication of infection from BAL fluid. We conclude that in CF, infection initiates and sustains airway inflammation.
Collapse
Affiliation(s)
- David S Armstrong
- Department of Paediatrics, Monash Medical Centre, Monash University, Clayton, Victoria, Australia
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Bush A, Accurso F, Macnee W, Lazarus SC, Abraham E. Cystic fibrosis, pediatrics, control of breathing, pulmonary physiology and anatomy, and surfactant biology in AJRCCM in 2004. Am J Respir Crit Care Med 2005; 171:545-53. [PMID: 15753484 DOI: 10.1164/rccm.2412007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Andrew Bush
- Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Box C272, Room 5503, Denver, CO 80262-0001, USA
| | | | | | | | | |
Collapse
|
15
|
Provencher S, Jais X, Sitbon O. Bosentan therapy for pulmonary arterial hypertension. Future Cardiol 2005; 1:299-309. [DOI: 10.1517/14796678.1.3.299] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance potentially leading to right heart failure and death. Since endothelins may play a pathogenic role in the development of the disease, endothelin receptor antagonists have been proposed for the treatment of this condition. Bosentan (Tracleer®), an oral nonselective ETA/ETB endothelin receptor antagonist, has been shown to improve exercise capacity, quality of life and hemodynamics of patients with PAH in short-term trials. These improvements were sustained and a long-term observational study on idiopathic PAH patients suggested a favorable effect on survival in this subset. The present report summarizes the pharmacology, clinical efficacy and safety profile of bosentan with an overview of the current therapies available for the treatment of PAH.
Collapse
Affiliation(s)
- Steeve Provencher
- AP-HP – Université Paris-Sud, Hôpital Antoine Béclère, Centre des Maladies, Vasculaires Pulmonaires (UPRES EA 2705), Service de Pneumologie et Réanimation, Clamart, 157 rue de la Porte de Trivaux, 92140 Clamart, France
| | - Xavier Jais
- AP-HP – Université Paris-Sud, Hôpital Antoine Béclère, Centre des Maladies Vasculaires Pulmonaires (UPRES EA 2705), Service de Pneumologie et Réanimation, Clamart, 157 rue de la Porte de Trivaux, 92140 Clamart, France.
| | - Olivier Sitbon
- AP-HP – Université Paris-Sud, Hôpital Antoine Béclère, Centre des Maladies Vasculaires Pulmonaires (UPRES EA 2705), Service de Pneumologie et Réanimation, Clamart, 157 rue de la Porte de Trivaux, 92140 Clamart, France.
| |
Collapse
|
16
|
Abstract
Congenital bilateral absence of the vas deferens (CBAVD) is a form of infertility with an autosomal recessive genetic background in otherwise healthy males. CBAVD is caused by cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations on both alleles in approximately 80% of cases. Striking CFTR genotypic differences are observed in cystic fibrosis (CF) and in CBAVD. The 5T allele is a CBAVD mutation with incomplete penetrance. Recent evidence confirmed that a second polymorphic locus exists and is a major CFTR modifier. The development of minigene models have led to results suggesting that CFTR exon 9 is skipped in humans because of unusual suboptimal 5' splice sites. An extremely rare T3 allele has been reported and it has recently been confirmed that the T3 allele dramatically increases exon 9 skipping and should be considered as a 'CF' mutation. Routine testing for the most prevalent mutations in the CF Caucasian population will miss most CFTR gene alterations, which can be detected only through exhaustive scanning of CFTR sequences. Finally, a higher than expected frequency of CFTR mutations and/or polymorphisms is now found in a growing number of monosymptomatic disorders, which creates a dilemma for setting nosologic boundaries between CF and diseases related to CFTR.
Collapse
Affiliation(s)
- Mireille Claustres
- Laboratoire de Génétique Moléculaire et Chromosomique, CHU de Montpellier, Institut Universitaire de Recherche Clinique (IURC), 641 Avenue du Doyen Gaston Giraud, 34093, Montpellier Cedex 5, France.
| |
Collapse
|
17
|
Gilljam M, Ellis L, Corey M, Zielenski J, Durie P, Tullis DE. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest 2004; 126:1215-24. [PMID: 15486385 DOI: 10.1378/chest.126.4.1215] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
OBJECTIVE To define the clinical characteristics and diagnostic parameters of patients with cystic fibrosis (CF) diagnosed in adulthood. DESIGN Retrospective cohort study. SETTING Tertiary care center. PATIENTS AND METHODS All patients with a diagnosis of CF made at the Toronto CF Clinics between 1960 and June 2001. Data were collected prospectively and analyzed retrospectively. RESULTS There were 73 of 1,051 patients (7%) with CF diagnosed in adulthood. Over time, an increasing number and proportion of patients received a diagnosis in adulthood: 27 patients (3%) before 1990, compared to 46 patients (18%) after 1990 (p < 0.001). The mean sweat chloride level was lower for those with CF diagnosed as adults, compared to those with a diagnosis as children (75 +/- 26 mmol/L and 100 +/- 19 mmol/L, respectively; p < 0.001) [mean +/- SD], and adults were more likely to have pancreatic sufficiency (PS) than children (73% vs 13%, respectively; p < 0.0001). In 46 adults who received a diagnosis since 1990, the reason for the initial sweat test was pancreatitis (2 patients, 4%), pulmonary symptoms (18 patients, 39%), pulmonary and GI symptoms (10 patients, 22%), infertility (12 patients, 26%), and genetic screening (4 patients, 9%). Other manifestations were biliary cirrhosis (one patient) and diabetes mellitus (four patients, 9%). The diagnosis could be confirmed by sweat test alone in 30 of 46 patients (65%), by mutation analysis alone in 15 patients (33%), and by a combination in 31 patients (67%). Nasal potential difference (PD) measurements alone confirmed the diagnosis in the remaining 15 patients (33%). CONCLUSION Patients with CF presenting in adulthood often have PS, inconclusive sweat test results, and a high prevalence of mutations that are not commonly seen in CF diagnosed in childhood. Although most patients have lung disease of variable degrees, single-organ manifestations such as congenital bilateral absence of the vas deferens and pancreatitis are seen. Repeated sweat tests and extensive mutation analysis are often required. Nasal PD may aid the diagnosis, but has not been standardized for clinical diagnosis.
Collapse
Affiliation(s)
- Marita Gilljam
- Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Goteborg University, Goteborg, Sweden
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
Animal models of cystic fibrosis, in particular several different mutant mouse strains obtained by homologous recombination, have contributed considerably to our understanding of CF pathology. In this review, we describe and compare the main phenotypic features of these models. Recent and possible future developments in this field are discussed.
Collapse
Affiliation(s)
- Bob J Scholte
- Department of Cell Biology, Erasmus Medical Centre, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
| | | | | | | |
Collapse
|
19
|
Pradal U, Piacentini GL. Cystic fibrosis patients, infertile men, and their noses. Am J Respir Crit Care Med 2004; 169:141-2. [PMID: 14718229 DOI: 10.1164/rccm.2311005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|